GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Cyclically Adjusted Price-to-FCF

Heidelberg Pharma AG (XTER:HPHA) Cyclically Adjusted Price-to-FCF : (As of Sep. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heidelberg Pharma AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Cyclically Adjusted Price-to-FCF Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heidelberg Pharma AG Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF falls into.



Heidelberg Pharma AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Heidelberg Pharma AG's Cyclically Adjusted FCF per Share for the quarter that ended in May. 2024 is calculated as:

For example, Heidelberg Pharma AG's adjusted Free Cash Flow per Share data for the three months ended in May. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of May. 2024 (Change)*Current CPI (May. 2024)
=-0.133/125.7761*125.7761
=-0.133

Current CPI (May. 2024) = 125.7761.

Heidelberg Pharma AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201408 -0.034 99.823 -0.043
201411 -0.058 99.543 -0.073
201502 -0.103 99.217 -0.131
201505 -0.150 100.417 -0.188
201508 -0.112 100.617 -0.140
201511 -0.178 99.717 -0.225
201602 -0.128 99.317 -0.162
201605 -0.107 100.617 -0.134
201608 -0.137 101.017 -0.171
201611 -0.188 100.517 -0.235
201702 -0.153 101.217 -0.190
201705 -0.142 101.817 -0.175
201708 -0.070 102.617 -0.086
201711 -0.208 102.117 -0.256
201802 -0.121 102.317 -0.149
201805 -0.054 103.917 -0.065
201808 -0.097 104.517 -0.117
201811 -0.118 104.217 -0.142
201902 -0.120 103.817 -0.145
201905 -0.104 105.418 -0.124
201908 -0.014 106.018 -0.017
201911 -0.099 105.318 -0.118
202002 -0.174 105.618 -0.207
202005 -0.131 106.018 -0.155
202008 -0.187 106.018 -0.222
202011 -0.142 105.018 -0.170
202102 -0.223 107.018 -0.262
202105 -0.224 108.170 -0.260
202108 -0.192 109.118 -0.221
202111 -0.217 110.173 -0.248
202202 -0.192 111.754 -0.216
202205 0.396 115.760 0.430
202208 -0.212 116.709 -0.228
202211 -0.169 119.872 -0.177
202302 -0.236 121.454 -0.244
202305 -0.169 122.824 -0.173
202308 -0.182 123.878 -0.185
202311 -0.155 123.668 -0.158
202402 -0.240 124.511 -0.242
202405 -0.133 125.776 -0.133

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heidelberg Pharma AG  (XTER:HPHA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Heidelberg Pharma AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Industry
Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines